Apogee Therapeutics, Inc. (APGE) NASDAQ
78.71
-0.59(-0.74%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
78.71
-0.59(-0.74%)
Currency In USD
Address
221 Crescent Street
Waltham, MA 02453
United States of America (the)
Phone
650-394-5230
Sector
Healthcare
Industry
Biotechnology
Employees
196
First IPO Date
July 14, 2023
| Name | Title | Pay | Year Born |
| Michael Thomas Henderson | Chief Executive Officer & Director | 1.29M | 1990 |
| Carl Linden Dambkowski | Chief Medical Officer | 855,900 | 1985 |
| Jane Pritchett V. Henderson | Chief Financial Officer | 855,900 | 1966 |
| Rebecca Dabora | Chief Development Officer | 0 | 1960 |
| Noel Kurdi | Vice President of Investor Relations | 0 | N/A |
| Wendy Aspden-Curran | Senior Vice President of Clinical Operations | 0 | N/A |
| Emily Cox | SVP & Head of People | 0 | N/A |
| Mehrak Kiankarimi | Senior Vice President of Program & Portfolio | 0 | N/A |
| Dan Mulreany | Chief Business Officer | 0 | N/A |
| Drew Badger | Senior Vice President and Head of Regulatory Affairs & Toxicology | 0 | N/A |
| Monica Forbes | Senior Vice President of Finance | 0 | 1976 |
| Matthew Batters | Chief Legal Officer & Corporate Secretary | 0 | 1976 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.